3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Motor Activity
2
Breast Neoplasms
2
Weight Loss
1
Uterine Cervical Dysplasia
1
Polycystic Ovary Syndrome
1
Papillomavirus Infections
1
Obesity
1
Insulin Resistance
1
Infertility, Female
1
Infections
1
Cognitive Dysfunction
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
36
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
29
Papillomavirus Vaccines
22
Vaccines
11
Human Papillomavirus Recombinant Vaccine nonavalent
11
Radiotherapy, Intensity-Modulated
7
Human Papillomavirus DNA Tests
7
Colposcopy
7
Cisplatin
7
Educational Status
6
Carboplatin
6
Blood Specimen Collection
6
Vaccines, Synthetic
5
Specimen Handling
5
Early Intervention, Educational
5
Vaginal Smears
4
Methods
4
Engerix-B
4
fludarabine
3
epigallocatechin gallate
3
artesunic acid
3
artemisinin
3
Watchful Waiting
3
Surveys and Questionnaires
3
Patient Navigation
3
Paclitaxel
3
Imiquimod
3
Hepatitis A Vaccines
3
Cyclophosphamide
3
halofantrine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Papillomavirus Infections
×
lime
×
Clear all
NCT02346227
2018-10-12
KINVAV
Universiteit Antwerpen
Phase 3
Completed
327 enrolled